FDA Clears 'Baxfendy,' a First-in-Class Hypertension Drug, When Will Korea Get It?

Disclaimer — This article is for informational purposes only and does not replace medical diagnosis or prescription. Any change to hypertension treatment must be discussed with a healthcare professional.

1. Research context

On May 18, the FDA approved AstraZeneca's new hypertension drug Baxfendy (baxdrostat). This isn't just another launch — Baxfendy is the world's first aldosterone synthase inhibitor (ASI), the first new mechanism of action in hypertension care in nearly 30 years.

Image related to FDA Clears 'Baxfendy,' a First-in-Class Hypertension Drug, When Will Korea Get It?

*Photo by Sincerely Media on Unsplash*

2. What is Baxfendy?

Existing hypertension drugs fall into roughly five classes: ACE inhibitors, ARBs, calcium channel blockers, beta blockers, and diuretics. Baxfendy belongs to none of them — it's a brand new class.

Generic name: baxdrostat
Class: aldosterone synthase inhibitor (ASI)
Form: oral, once daily
Approval date: 2026-05-18 (FDA)
Developer: AstraZeneca
Commercial launch: early June 2026 (US)
Use: as an add-on for patients whose blood pressure is not controlled despite taking two or more existing antihypertensives

Aldosterone is a hormone produced by the adrenal glands that retains sodium and water and pushes blood pressure up. Baxfendy blocks the enzyme (CYP11B2) that produces aldosterone, cutting hormone production at the source. If ARBs and ACE inhibitors act downstream, Baxfendy intervenes further upstream.

3. What did the trials show?

The approval rests on the BaxHTN Phase III trial. Pulling from PharmExec and Drugs.com:

Metric	Result
Trial	BaxHTN Phase III
Population	Hypertensive patients uncontrolled on 2+ drugs
Duration	12 weeks
2mg dose — systolic BP reduction	~−9.8 mmHg vs. placebo
1mg dose — systolic BP reduction	~−8.7 mmHg vs. placebo

A "−9.8 mmHg vs. placebo" reduction is clinically meaningful. Worth noting: that's a placebo-adjusted figure, not an absolute drop.

"For resistant hypertension patients who aren't controlled even on two ARBs or ACE inhibitors, this opens a new option. It's not a first-line drug for typical hypertension cases."
— The Cardiology Advisor summary

4. Who can be prescribed Baxfendy?

The label is clear.

Patient population: adults with hypertension uncontrolled on two or more existing drugs (resistant or inadequately controlled)
Mode of use: add-on to existing therapy
Not first-line: not approved as monotherapy for initial treatment

The point: this is not a drug for someone newly diagnosed with hypertension. Resistant hypertension affects roughly 10–20% of all hypertensive patients, so the addressable market isn't small.

Image related to FDA Clears 'Baxfendy,' a First-in-Class Hypertension Drug, When Will Korea Get It?, image 2

*Photo by Towfiqu barbhuiya on Unsplash*

5. Side effects and safety

Because the drug lowers aldosterone, certain adverse events have been reported.

Hyperkalemia — less aldosterone means less potassium excretion. Routine blood tests recommended.
Hyponatremia
Hypotension (especially with multi-drug combinations)
Adrenal function monitoring may be needed

HCPLive emphasizes that this is a drug used "on top of background therapy." It is not meant to replace existing treatment.

6. When will Korea see it?

Approval in Korea requires a separate review by the Ministry of Food and Drug Safety. AstraZeneca typically rolls out globally in a US → Europe → Asia sequence.

US launch: early June 2026
EMA review (Europe): ongoing — exact timing to be confirmed via corporate disclosures
Korean approval: no schedule announced. Historically, 6 months to 2 years after US approval is common.
National health insurance coverage: a separate reimbursement review follows local approval

Like Wegovy, pricing will be a focal point when a global non-reimbursed drug arrives in Korea. Once the US list price is published, comparable estimates will be possible.

Image related to FDA Clears 'Baxfendy,' a First-in-Class Hypertension Drug, When Will Korea Get It?, image 3

*Photo by Anna Evans on Unsplash*

7. TL;DR

FDA approval 2026-05-18; US launch in early June
World's first aldosterone synthase inhibitor (ASI)
Target: resistant hypertension uncontrolled on 2+ existing drugs
BaxHTN Phase III: ~−9.8 mmHg systolic vs. placebo (2mg)
Monitor for hyperkalemia and hypotension
Korean approval timing TBD

Korean patients can't access Baxfendy right away, but for those whose hypertension is poorly controlled, a new long-term option is on the horizon. Don't change or stop current medication on your own — review options with your doctor once the drug lands locally.

Check out more from our health category, or the #FDA and #new-drug tags. Our piece on small lifestyle changes for heart health is a useful companion read.

8. Sources

Sources: AstraZeneca press release, Drugs.com, The Cardiology Advisor, PharmExec, TCTMD, HCPLive